Works by Moreau, Philippe


Results: 356
    1
    2
    3
    4
    5
    6

    Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant.

    Published in:
    EJHaem, 2022, v. 3, n. 2, p. 484, doi. 10.1002/jha2.398
    By:
    • Jullien, Maxime;
    • Coste‐Burel, Marianne;
    • Clemenceau, Beatrice;
    • Letailleur, Valentin;
    • Guillaume, Thierry;
    • Peterlin, Pierre;
    • Garnier, Alice;
    • Bourgeois, Amandine Le;
    • Imbert, Berthe‐Marie;
    • Ollier, Jocelyn;
    • Grain, Audrey;
    • Touzeau, Cyrille;
    • Moreau, Philippe;
    • Béné, Marie C;
    • Vié, Henri;
    • Chevallier, Patrice
    Publication type:
    Article
    7

    Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients.

    Published in:
    EJHaem, 2021, v. 2, n. 3, p. 520, doi. 10.1002/jha2.242
    By:
    • Chevallier, Patrice;
    • Coste‐Burel, Marianne;
    • Le Bourgeois, Amandine;
    • Peterlin, Pierre;
    • Garnier, Alice;
    • Béné, Marie C.;
    • Imbert, Berthe‐Marie;
    • Drumel, Thomas;
    • Le Gouill, Steven;
    • Moreau, Philippe;
    • Mahe, Beatrice;
    • Dubruille, Viviane;
    • Blin, Nicolas;
    • Lok, Anne;
    • Touzeau, Cyrille;
    • Gastinne, Thomas;
    • Jullien, Maxime;
    • Vanthygem, Sophie;
    • Guillaume, Thierry
    Publication type:
    Article
    8

    Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching

    Published in:
    EJHaem, 2021, v. 2, n. 1, p. 66, doi. 10.1002/jha2.129
    By:
    • Moreau, Philippe;
    • Hulin, Cyrille;
    • Zweegman, Sonja;
    • Hashim, Mahmoud;
    • Hu, Yannan;
    • Heeg, Bart;
    • Boer, Carla;
    • Vanquickelberghe, Veronique;
    • Kampfenkel, Tobias;
    • He, Jianming;
    • Lam, Annette;
    • Cote, Sarah;
    • Sonneveld, Pieter
    Publication type:
    Article
    9

    Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma.

    Published in:
    EJHaem, 2021, v. 2, n. 1, p. 48, doi. 10.1002/jha2.120
    By:
    • Richardson, Paul G.;
    • Jagannath, Sundar;
    • Chari, Ajai;
    • Vogl, Dan T.;
    • Dimopoulos, Meletios A.;
    • Moreau, Philippe;
    • Dingli, David;
    • Wei, Lee‐Jen;
    • Richter, Joshua;
    • Biran, Noa;
    • Siegel, David;
    • Reichmann, William;
    • Li, Lingling;
    • Tang, Shijie;
    • Saint‐Martin, Jean‐Richard;
    • Joshi, Anita;
    • Kauffman, Michael;
    • Shah, Jatin;
    • Shacham, Sharon;
    • Lonial, Sagar
    Publication type:
    Article
    10

    Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible.

    Published in:
    EJHaem, 2020, v. 1, n. 2, p. 481, doi. 10.1002/jha2.77
    By:
    • Sonneveld, Pieter;
    • Mateos, María‐Victoria;
    • Alegre, Adrian;
    • Facon, Thierry;
    • Hulin, Cyrille;
    • Hashim, Mahmoud;
    • Vincken, Talitha;
    • Kampfenkel, Tobias;
    • Cote, Sarah;
    • He, Jianming;
    • Lam, Annette;
    • Moreau, Philippe
    Publication type:
    Article
    11

    RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation.

    Published in:
    EJHaem, 2020, v. 1, n. 1, p. 1, doi. 10.1002/jha2.8
    By:
    • Le Calvez, Baptiste;
    • Le Bris, Yannick;
    • Herbreteau, Guillaume;
    • Jamet, Bastien;
    • Bossard, Céline;
    • Tessoulin, Benoit;
    • Gastinne, Thomas;
    • Mahé, Béatrice;
    • Dubruille, Viviane;
    • Blin, Nicolas;
    • Antier, Chloé;
    • Theisen, Olivier;
    • Kraeber-Bodéré, Françoise;
    • Le Gouill, Steven;
    • Béné, Marie C.;
    • Moreau, Philippe;
    • Touzeau, Cyrille
    Publication type:
    Article
    12

    Are the Immune Properties of Mesenchymal Stem Cells from Wharton's Jelly Maintained during Chondrogenic Differentiation?

    Published in:
    Journal of Clinical Medicine, 2020, v. 9, n. 2, p. 423, doi. 10.3390/jcm9020423
    By:
    • Voisin, Charlotte;
    • Cauchois, Ghislaine;
    • Reppel, Loïc;
    • Laroye, Caroline;
    • Louarn, Laetitia;
    • Schenowitz, Chantal;
    • Sonon, Paulin;
    • Poras, Isabelle;
    • Wang, Valentine;
    • D. Carosella, Edgardo;
    • Benkirane-Jessel, Nadia;
    • Moreau, Philippe;
    • Rouas-Freiss, Nathalie;
    • Bensoussan, Danièle;
    • Huselstein, Céline
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19

    Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins ( FB2 regimen) reduced-intensity conditioning regimen ( RIC) allogeneic stem cell transplantation (allo- SCT).

    Published in:
    European Journal of Haematology, 2013, v. 90, n. 3, p. 177, doi. 10.1111/ejh.12049
    By:
    • Bourgeois, Amandine;
    • Lestang, Elsa;
    • Guillaume, Thierry;
    • Delaunay, Jacques;
    • Ayari, Sameh;
    • Blin, Nicolas;
    • Clavert, Aline;
    • Tessoulin, Benoit;
    • Dubruille, Viviane;
    • Mahe, Beatrice;
    • Roland, Virginie;
    • Gastinne, Thomas;
    • Gouill, Steven;
    • Moreau, Philippe;
    • Mohty, Mohamad;
    • Planche, Lucie;
    • Chevallier, Patrice
    Publication type:
    Article
    20

    Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.

    Published in:
    European Journal of Haematology, 2012, v. 88, n. 3, p. 249, doi. 10.1111/j.1600-0609.2011.01729.x
    By:
    • Yakoub-Agha, Ibrahim;
    • Mary, Jean-Yves;
    • Hulin, Cyrille;
    • Doyen, Chantal;
    • Marit, Gérald;
    • Benboubker, Lotfi;
    • Voillat, Laurent;
    • Moreau, Philippe;
    • Berthou, Christian;
    • Stoppa, Anne-Marie;
    • Maloisel, Frédéric;
    • Rodon, Philippe;
    • Dib, Mamoun;
    • Pegourie, Brigitte;
    • Casassus, Philippe;
    • Slama, Borhane;
    • Damaj, Ghandi;
    • Zerbib, Robert;
    • Harousseau, Jean-Luc;
    • Mohty, Mohamad
    Publication type:
    Article
    21
    22
    23
    24

    Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis.

    Published in:
    International Journal of Computer Assisted Radiology & Surgery, 2020, v. 15, n. 1, p. 129, doi. 10.1007/s11548-019-02015-y
    By:
    • Morvan, Ludivine;
    • Carlier, Thomas;
    • Jamet, Bastien;
    • Bailly, Clément;
    • Bodet-Milin, Caroline;
    • Moreau, Philippe;
    • Kraeber-Bodéré, Françoise;
    • Mateus, Diana
    Publication type:
    Article
    25

    Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma.

    Published in:
    Applied Health Economics & Health Policy, 2013, v. 11, n. 2, p. 129, doi. 10.1007/s40258-013-0011-7
    By:
    • Perrier, Lionel;
    • Lefranc, Anne;
    • Pérol, David;
    • Quittet, Philippe;
    • Schmidt-Tanguy, Aline;
    • Siani, Carole;
    • Peretti, Christian;
    • Favier, Bertrand;
    • Biron, Pierre;
    • Moreau, Philippe;
    • Bay, Jacques;
    • Lissandre, Séverine;
    • Jardin, Fabrice;
    • Espinouse, Daniel;
    • Sebban, Catherine
    Publication type:
    Article
    26

    Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

    Published in:
    Advances in Therapy, 2024, v. 41, n. 4, p. 1576, doi. 10.1007/s12325-024-02797-x
    By:
    • Einsele, Hermann;
    • Moreau, Philippe;
    • Bahlis, Nizar;
    • Bhutani, Manisha;
    • Vincent, Laure;
    • Karlin, Lionel;
    • Perrot, Aurore;
    • Goldschmidt, Hartmut;
    • van de Donk, Niels W. C. J.;
    • Ocio, Enrique M.;
    • Martinez-Lopez, Joaquin;
    • Rodríguez-Otero, Paula;
    • Dytfeld, Dominik;
    • Diels, Joris;
    • Strulev, Vadim;
    • Haddad, Imene;
    • Renaud, Thomas;
    • Ammann, Eric;
    • Cabrieto, Jedelyn;
    • Perualila, Nolen
    Publication type:
    Article
    27

    Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.

    Published in:
    Advances in Therapy, 2024, v. 41, n. 2, p. 696, doi. 10.1007/s12325-023-02738-0
    By:
    • Moreau, Philippe;
    • Mateos, María-Victoria;
    • Gonzalez Garcia, Maria Esther;
    • Einsele, Hermann;
    • De Stefano, Valerio;
    • Karlin, Lionel;
    • Lindsey-Hill, Joanne;
    • Besemer, Britta;
    • Vincent, Laure;
    • Kirkpatrick, Suriya;
    • Delforge, Michel;
    • Perrot, Aurore;
    • van de Donk, Niels W. C. J.;
    • Pawlyn, Charlotte;
    • Manier, Salomon;
    • Leleu, Xavier;
    • Martinez-Lopez, Joaquin;
    • Ghilotti, Francesca;
    • Diels, Joris;
    • Morano, Raúl
    Publication type:
    Article
    28

    Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.

    Published in:
    Advances in Therapy, 2023, v. 40, n. 5, p. 2412, doi. 10.1007/s12325-023-02480-7
    By:
    • Moreau, Philippe;
    • van de Donk, Niels W. C. J.;
    • Delforge, Michel;
    • Einsele, Hermann;
    • De Stefano, Valerio;
    • Perrot, Aurore;
    • Besemer, Britta;
    • Pawlyn, Charlotte;
    • Karlin, Lionel;
    • Manier, Salomon;
    • Leleu, Xavier;
    • Weisel, Katja;
    • Ghilotti, Francesca;
    • Diels, Joris;
    • Elsada, Ahmed;
    • Morano, Raul;
    • Strulev, Vadim;
    • Pei, Lixia;
    • Kobos, Rachel;
    • Smit, Jennifer
    Publication type:
    Article
    29
    30
    31
    32

    Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.

    Published in:
    Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.262884
    By:
    • Alberge, Jean-Baptiste;
    • Kraeber-Bodéré, Françoise;
    • Jamet, Bastien;
    • Touzeau, Cyrille;
    • Caillon, Hélène;
    • Wuilleme, Soraya;
    • Béné, Marie-Christine;
    • Kampfenkel, Tobias;
    • Sonneveld, Pieter;
    • van Duin, Mark;
    • Avet-Loiseau, Herve;
    • Corre, Jill;
    • Magrangeas, Florence;
    • Carlier, Thomas;
    • Bodet-Milin, Caroline;
    • Chérel, Michel;
    • Moreau, Philippe;
    • Minvielle, Stéphane;
    • Bailly, Clément
    Publication type:
    Article
    33

    Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.

    Published in:
    Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 257, doi. 10.2967/jnumed.121.262884
    By:
    • Alberge, Jean-Baptiste;
    • Kraeber-Bodéré, Françoise;
    • Jamet, Bastien;
    • Touzeau, Cyrille;
    • Caillon, Hélène;
    • Wuilleme, Soraya;
    • Béné, Marie-Christine;
    • Kampfenkel, Tobias;
    • Sonneveld, Pieter;
    • Duin, Mark van;
    • Avet-Loiseau, Herve;
    • Corre, Jill;
    • Magrangeas, Florence;
    • Carlier, Thomas;
    • Bodet-Milin, Caroline;
    • Chérel, Michel;
    • Moreau, Philippe;
    • Minvielle, Stéphane;
    • Bailly, Clément
    Publication type:
    Article
    34

    Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.

    Published in:
    Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.262884
    By:
    • Alberge, Jean-Baptiste;
    • Kraeber-Bodéré, Françoise;
    • Cyrille Touzeau, Bastien Jamet2,3;
    • Caillon, Hélène;
    • Wuilleme, Soraya;
    • Béné, Marie-Christine;
    • Kampfenkel, Tobias;
    • Sonneveld, Pieter;
    • Duin, Mark van;
    • Avet-Loiseau, Herve;
    • Corre, Jill;
    • Magrangeas, Florence;
    • Carlier, Thomas;
    • Bodet-Milin, Caroline;
    • Chérel, Michel;
    • Moreau, Philippe;
    • Minvielle, Stéphane;
    • Bailly, Clément
    Publication type:
    Article
    35

    Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.

    Published in:
    Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.262884
    By:
    • Alberge, Jean-Baptiste;
    • Kraeber-Bodéré, Françoise;
    • Jamet, Bastien;
    • Touzeau, Cyrille;
    • Caillon, Hélène;
    • Wuilleme, Soraya;
    • Béné, Marie-Christine;
    • Kampfenkel, Tobias;
    • Sonneveld, Pieter;
    • van Duin, Mark;
    • Avet-Loiseau, Herve;
    • Corre, Jill;
    • Magrangeas, Florence;
    • Carlier, Thomas;
    • Bodet-Milin, Caroline;
    • Chérel, Michel;
    • Moreau, Philippe;
    • Minvielle, Stéphane;
    • Bailly, Clément
    Publication type:
    Article
    36

    Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.

    Published in:
    Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.262884
    By:
    • Alberge, Jean-Baptiste;
    • Kraeber-Bodéré, Françoise;
    • Jamet, Bastien;
    • Touzeau, Cyrille;
    • Caillon, Hélène;
    • Wuilleme, Soraya;
    • Béné, Marie-Christine;
    • Kampfenkel, Tobias;
    • Sonneveld, Pieter;
    • van Duin, Mark;
    • Avet-Loiseau, Herve;
    • Corre, Jill;
    • Magrangeas, Florence;
    • Carlier, Thomas;
    • Bodet-Milin, Caroline;
    • Chérel, Michel;
    • Moreau, Philippe;
    • Minvielle, Stéphane;
    • Bailly, Clément
    Publication type:
    Article
    37

    Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.

    Published in:
    Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.262884
    By:
    • Alberge, Jean-Baptiste;
    • Kraeber-Bodéré, Françoise;
    • Jamet, Bastien;
    • Touzeau, Cyrille;
    • Caillon, Hélène;
    • Wuilleme, Soraya;
    • Béné, Marie-Christine;
    • Kampfenkel, Tobias;
    • Sonneveld, Pieter;
    • van Duin, Mark;
    • Avet-Loiseau, Herve;
    • Corre, Jill;
    • Magrangeas, Florence;
    • Carlier, Thomas;
    • Bodet-Milin, Caroline;
    • Chérel, Michel;
    • Moreau, Philippe;
    • Minvielle, Stéphane;
    • Bailly, Clément
    Publication type:
    Article
    38

    Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.

    Published in:
    Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.262884
    By:
    • Alberge, Jean-Baptiste;
    • Kraeber-Bodéré, Françoise;
    • Jamet, Bastien;
    • Touzeau, Cyrille;
    • Caillon, Hélène;
    • Wuilleme, Soraya;
    • Béné, Marie-Christine;
    • Kampfenkel, Tobias;
    • Sonneveld, Pieter;
    • van Duin, Mark;
    • Avet-Loiseau, Herve;
    • Corre, Jill;
    • Magrangeas, Florence;
    • Carlier, Thomas;
    • Bodet-Milin, Caroline;
    • Chérel, Michel;
    • Moreau, Philippe;
    • Minvielle, Stéphane;
    • Bailly, Clément
    Publication type:
    Article
    39
    40
    41
    42

    Phase I study of zoledronic acid combined with escalated doses of interleukine‐2 for early in vivo generation of Vγ9Vδ2 T‐cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.

    Published in:
    American Journal of Hematology, 2024, v. 99, n. 3, p. 350, doi. 10.1002/ajh.27191
    By:
    • Jullien, Maxime;
    • Guillaume, Thierry;
    • Le Bourgeois, Amandine;
    • Peterlin, Pierre;
    • Garnier, Alice;
    • Eveillard, Marion;
    • Le Bris, Yannick;
    • Bouzy, Simon;
    • Tessoulin, Benoît;
    • Gastinne, Thomas;
    • Dubruille, Viviane;
    • Touzeau, Cyrille;
    • Mahé, Béatrice;
    • Blin, Nicolas;
    • Lok, Anne;
    • Vantyghem, Sophie;
    • Sortais, Clara;
    • Antier, Chloé;
    • Moreau, Philippe;
    • Scotet, Emmanuel
    Publication type:
    Article
    43

    Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.

    Published in:
    American Journal of Hematology, 2023, v. 98, n. 1, p. E15, doi. 10.1002/ajh.26602
    By:
    • Dimopoulos, Meletios A.;
    • Moreau, Philippe;
    • Augustson, Bradley;
    • Castro, Nelson;
    • Pika, Tomas;
    • Delimpasi, Sosana;
    • De la Rubia, Javier;
    • Maiolino, Angelo;
    • Reiman, Tony;
    • Martinez‐Lopez, Joaquin;
    • Martin, Thomas;
    • Mikhael, Joseph;
    • Yong, Kwee;
    • Risse, Marie‐Laure;
    • Asset, Gaelle;
    • Marion, Sylvia;
    • Hajek, Roman
    Publication type:
    Article
    44

    Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial.

    Published in:
    American Journal of Hematology, 2022, v. 97, n. 4, p. 481, doi. 10.1002/ajh.26480
    By:
    • Terpos, Evangelos;
    • Dimopoulos, Meletios A.;
    • Boccadoro, Mario;
    • Delimpasi, Sosana;
    • Beksac, Meral;
    • Katodritou, Eirini;
    • Moreau, Philippe;
    • Pompa, Alessandra;
    • Symeonidis, Argiris;
    • Bila, Jelena;
    • Oriol, Albert;
    • Mateos, Maria‐Victoria;
    • Einsele, Hermann;
    • Orfanidis, Ioannis;
    • Gries, Katharine S.;
    • Fastenau, John;
    • Liu, Kevin;
    • He, Jianming;
    • Kampfenkel, Tobias;
    • Qiu, Yanping
    Publication type:
    Article
    45

    Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

    Published in:
    American Journal of Hematology, 2022, v. 97, n. 3, p. E83, doi. 10.1002/ajh.26434
    By:
    • Delimpasi, Sosana;
    • Mateos, Maria Victoria;
    • Auner, Holger W.;
    • Gavriatopoulou, Maria;
    • Dimopoulos, Meletios A.;
    • Quach, Hang;
    • Pylypenko, Halyna;
    • Hájek, Roman;
    • Leleu, Xavier;
    • Dolai, Tuphan Kanti;
    • Sinha, Dinesh Kumar;
    • Venner, Christopher P.;
    • Benjamin, Reuben;
    • Garg, Mamta Krishnan;
    • Doronin, Vadim;
    • Levy, Yair;
    • Moreau, Philippe;
    • Chai, Yi;
    • Arazy, Melina;
    • Shah, Jatin
    Publication type:
    Article
    46
    47
    48

    Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.

    Published in:
    American Journal of Hematology, 2021, v. 96, n. 4, p. 418, doi. 10.1002/ajh.26083
    By:
    • Kaufman, Jonathan L.;
    • Gasparetto, Cristina;
    • Schjesvold, Fredrik H.;
    • Moreau, Philippe;
    • Touzeau, Cyrille;
    • Facon, Thierry;
    • Boise, Lawrence H.;
    • Jiang, Yanwen;
    • Yang, Xiaoqing;
    • Dunbar, Fengjiao;
    • Vishwamitra, Deeksha;
    • Unger, Stefanie;
    • Macartney, Tammy;
    • Pesko, John;
    • Yu, Yao;
    • Salem, Ahmed Hamed;
    • Ross, Jeremy A.;
    • Hong, Wan‐Jen;
    • Maciag, Paulo C.;
    • Pauff, James M.
    Publication type:
    Article
    49

    Switches of tyrosine‐kinase inhibitors in chronic phase of chronic myeloid leukemia in real life.

    Published in:
    American Journal of Hematology, 2018, v. 93, n. 10, p. E329, doi. 10.1002/ajh.25217
    By:
    • Norwood, James;
    • Pastoret, Cédric;
    • Luycx, Odile;
    • Le Coz, Marie‐Françoise;
    • Moreau, Philippe;
    • Trebouet, Adrien;
    • Niault, Mathilde;
    • Launay, Vincent;
    • Allangba, Olivier;
    • Bareau, Benoit;
    • Doncker, Violaine;
    • Grulois, Isabelle;
    • Jacomy, Dominique;
    • Le Dû, Katell;
    • Henry, Catherine;
    • Le Pabic, Estelle;
    • Boulland, Marie‐Laure;
    • Fest, Thierry;
    • Lamy, Thierry;
    • Escoffre‐Barbe, Martine
    Publication type:
    Article
    50

    Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma.

    Published in:
    American Journal of Hematology, 2018, v. 93, n. 8, p. 985, doi. 10.1002/ajh.25134
    By:
    • Leleu, Xavier;
    • Masszi, Tamas;
    • Bahlis, Nizar J.;
    • Viterbo, Luisa;
    • Baker, Bartrum;
    • Gimsing, Peter;
    • Maisnar, Vladimir;
    • Samoilova, Olga;
    • Rosiñol, Laura;
    • Langer, Christian;
    • Song, Kevin;
    • Izumi, Tohru;
    • Cleeland, Charles;
    • Berg, Deborah;
    • Lin, Huamao Mark;
    • Zhu, Yanyan;
    • Skacel, Tomas;
    • Moreau, Philippe;
    • Richardson, Paul G.
    Publication type:
    Article